Genome editing is not a ‘new’ technology. Genome editing has been around for somewhere between 25 to 30 years. This technology, while forming the foundation of gene therapy research, was ill-suited for the high-throughput requirements of a functional genomics platform technology. In this article, Ben Borgo of Agilent explores this in more detail, and explains why it is that to harness genome editing on an -omics scale, tools that are less expensive to produce and customise were required.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/05/The-rising-tide-of-functional-data-from.pdf” width=”100%” height=”900px” style=”border:0;”]